Altimmune submits IND for single dose intranasal COVID-19 vaccine

By The Science Advisory Board staff writers

November 25, 2020 -- Altimmune has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin a phase I clinical trial of its single-dose intranasal COVID-19 vaccine, AdCOVID.

AdCOVID is designed to stimulate broad immune responses including neutralizing antibodies and T-cell responses in the nasal cavity and respiratory tract. Preclinical studies of the vaccine were conducted at the University of Alabama at Birmingham. The phase I safety and immunogenicity study is planned to begin by the end of the year and interim data is expected in the first quarter of 2021.

AdCOVID is expected to have extended stability at room temperature allowing for cold chain-free shipment of the vaccine, where it can then be stored in common refrigerators. Due to the nature of intranasal administration, the vaccine is particularly well-suited for use in children, according to the company. The phase I study will include evaluation of the vaccine in children as young as 2 years of age.


Copyright © 2020 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.